Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

10.28 +0.31 (+3.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Tuesday's session: top gainers and losers
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Why NeoGenomics (NEO) Stock Is Nosediving
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 34.8% in the afternoon session after the company reported disappointing first-quarter 2025 earnings as sales fell below... 
Via StockStory
Topics Artificial Intelligence
Earnings Scheduled For April 29, 2025
 
Via Benzinga
Insights Ahead: NeoGenomics's Quarterly Earnings
 
Via Benzinga
Keep an eye on the top gainers and losers in Tuesday's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
These stocks are gapping in today's session
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings
 
Via Benzinga
NeoGenomics (NASDAQ:NEO) Misses Q1 Sales Targets, Stock Drops
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the... 
Via StockStory
NeoGenomics Reports First Quarter 2025 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics (NEO) Q1 Earnings Report Preview: What To Look For
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting earnings tomorrow morning. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
Deep Dive Into NeoGenomics Stock: Analyst Perspectives (5 Ratings)
 
Via Benzinga
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
From NeoGenomics, Inc.
Via Business Wire
Reflecting On Testing & Diagnostics Services Stocks’ Q4 Earnings: Guardant Health (NASDAQ:GH)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting... 
Via StockStory
NeoGenomics Completes Acquisition of Pathline
From NeoGenomics, Inc.
Via Business Wire
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers. 
Via StockStory
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
From NeoGenomics, Inc.
Via Business Wire
A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: Labcorp (NYSE:LH) Vs The Rest Of The Pack
Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers. 
Via StockStory
Q4 Testing & Diagnostics Services Earnings: RadNet (NASDAQ:RDNT) Impresses
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting... 
Via StockStory
3 Reasons to Sell NEO and 1 Stock to Buy Instead
NeoGenomics has gotten torched over the last six months - since September 2024, its stock price has dropped 36.8% to $9.98 per share. This may have investors wondering how to approach the situation. 
Via StockStory
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer
From NeoGenomics, Inc.
Via Business Wire
Earnings Scheduled For March 18, 2025
 
Via Benzinga
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst... 
Via StockStory
3 Small-Cap Stocks in Hot Water
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
From NeoGenomics, Inc.
Via Business Wire
3 Healthcare Stocks Skating on Thin Ice
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
What To Expect From RadNet’s (RDNT) Q4 Earnings
Diagnostic imaging company RadNet (NASDAQ:RDNT) will be reporting results tomorrow after market hours. Here’s what to look for. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.